UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 2921, 2019

MEDICAL INNOVATION HOLDINGS, INC.

(Exact name of Registrant as specified in its charter)

Colorado	000-27211	84-1469319
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

5805 State Bridge Road, Suite G-328, Duluth, GA 30097

(Address of Principal Executive Offices)

(866) 883-3793

(Registrant's Telephone Number, Including Area Code)

_______________________________________________

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b): None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

~~ITEM~~Item 41.01 ~~CHANGES~~Entry INinto ~~REGISTRANT’S~~a ~~CERTIFYING~~Material ~~ACCOUNTANT~~Definitive Agreement

~~Effective~~On June 2921, 2019, Medical Innovation Holdings, Inc. (the “Company”) ~~engaged~~entered ~~Prager~~into ~~Metis~~a ~~CPAs~~Securities Purchase Agreement and 8% Convertible Redeemable Promissory Note with Eagle Equities, LLC of(“Eagle ~~Hackensack~~Equities”) for $33,500 NJ(“Convertible Promissory asNote”). The Convertible Promissory Note is due June 21, 2020 and will not be eligible for conversion to free trading shares until six (6) months after the ~~Independent~~issuance ~~Registered~~of ~~Public~~the ~~Accountant~~Convertible toPromissory ~~Audit~~Note unless such shares are covered by a resale registration statement. The principal and accrued interest under the Convertible Promissory Note will be convertible into shares of common stock of the Company’s ~~financial~~at ~~statements~~a ~~for~~50% discount to the ~~fiscal~~lowest ~~year~~trading ~~ending~~price ~~April 30,~~during ~~2018~~the previous 20 trading days prior to the applicable conversion date. The ~~decision~~Company will provide and maintain a transfer agent reserve of equal to ~~change~~4x ~~accountants~~the ~~was~~discount ~~approved~~value byof the Convertible Promissory Note. If the Company’s ~~Board~~fails to maintain the share reserve at the 4x discount of ~~Directors~~the note 60 days after the issuance of the note, the conversion discount shall be increased by 10%. During the first 30 days after funding, the Convertible Promissory Note may be prepaid (in whole or in part) at 125% of the face amount plus any accrued interest. This shall increase by 5% every 30 days for the next 150 days. In no event, however, may the Convertible Promissory Note be prepaid after the six-month anniversary.

~~The engagement,~~Item effective June 29, 2019, of Prager Metis CPAs LLC as the new Independent Registered Public Accountant for the Company was necessary due to the resignation effective May 31, 2019 of MJF & Associates, the principal accountant which audited the Company’s financial statements for the fiscal year ended April 30, 2017, and which also had reviewed the Company’s previously filed quarterly reports on Form 10-Q for the periods ended July 31, 2017, October 31, 2017 and January 31, 20182.03 ~~The audit~~Creation ~~report by MJF & Associates on the financial statements~~ of ~~the~~Direct ~~Company~~Financial ~~for~~Obligation ~~the~~or ~~fiscal~~an ~~year~~Obligation ~~ended~~under ~~April 30, 2017 did not contain~~ an ~~adverse~~Off-Balance ~~opinion~~Sheet orArrangement ~~a disclaimer~~ of ~~opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles, except that the opinion was qualified for the ability of the Company to continue as~~ a ~~going concern.~~Registrant

~~During~~The ~~the~~disclosures ~~Company's~~under ~~fiscal~~Item ~~year ended April 30, 2018, and the period from May~~ 1,.01 ~~2018~~of ~~through~~this ~~May~~Current ~~31,~~Report ~~2019 (i) there were no disagreements with MJF & Associates~~ on ~~any~~Form matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures that, if not resolved to MJF & Associates satisfaction, would have caused MJF & Associates to make reference to the subject matter of the disagreement in connection with its reports and (ii) there were no “reportable events” as defined in Item 304(a)(1)(v) of Regulation S8-K.

~~A letter~~Item ~~addressed~~3.02 toUnregistered ~~the~~Sales ~~Commission stating whether MJF & Associates agrees with the statements made by the Company in response to Item 304(a)~~ of ~~Regulation~~Equity ~~S-K and, if not, stating the respects in which it does not agree is attached hereto as Exhibit 16.1.~~Securities

~~ITEM~~The information 9set forth in Item 1.01 ~~FINANCIAL~~is ~~STATEMENTS~~incorporated ~~AND~~by ~~EXHIBITS~~reference into this Item 3.02.

No.		Exhibits
16.1		Letter dated June 29, 2019 to the Securities and Exchange Commission from MJF & Associates

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS

SIGNATURES

Exhibit No.		Exhibits
10.1		Securities Purchase Agreement
10.2		Convertible Redeemable Promissory Note

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~1

~~Medical Innovation Holdings, Inc.~~SIGNATURES

~~By:~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~/s/ Ray~~Medical DeInnovation ~~Motte~~Holdings, Inc.

~~____________________~~By:

~~Ray~~/s/ DeRedgie ~~Motte~~Green

~~Title: CFO~~____________________

~~Date:~~Redgie ~~July 2, 2019~~Green

Title: Interim CEO

Date: July 9, 2019

Filing Compare · MEDICAL INNOVATION HOLDINGS, INC.